Phase 3 study of AstraZeneca covid vaccine conducted in US shows its safe and highly effective
|
The US, Chile And Peru interim trial data showed that the Oxford-AstraZeneca covid vaccine is safe and highly-effective, Reuters reports, citing the University of Oxford release.
Additional takeaways
“Phase 3 study of Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca Plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective.”
“The phase III vaccine trial shows in the US showed 79% efficacy in preventing symptomatic cases.”
“The vaccine has also shown to be 100% effective at preventing severe disease, death and hospitalization.”
The Anglo-Swedish drugmaker publishes the data from a study of more than 30,000 volunteers.
Market reaction
Markets shrug off the encouraging vaccine news, as the Turkish action continues to dent the investors’ sentiment, benefiting the US dollar across the board.
The US dollar index turns higher once again, now trading at 92.10, up 0.20% on the day.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.